LMT
LOCKHEED MARTIN CORP
(NYSE:LMT)
Balfour Capital Group Researched Lockheed Martin Corp on September 27th, 2023.
Lockheed Martin is a leading global aerospace, defense, and security company headquartered in Bethesda, Maryland. The company specializes in the research, design, development, manufacture, integration, and sustainment of advanced technology systems, products, and services. Its primary business areas include Aeronautics, Missiles and Fire Control, Rotary and Mission Systems, and Space.
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $409.18 on September 27th, 2023.
- Our designated price target stands at $510.00.
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More
ARGUS QUANTITATIVE
Argus Quantitative analyzes energy, commodities, and finance with data analytics
View More
ARGUS ANALYST
Argus Analyst Notes offers timely investment recommendations, insights.
View More
THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
View More
2025 Q1 EARNING REPORT
A Q1 report evaluates company financials for investors
Balfour Capital Group wants to clarify that our recommendation to Buy LOCKHEED MARTIN CORP (LMT) is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
ICE
INTERCONTINENTAL EXCHANGE INC
(NYSE:ICE)
Balfour Capital Group Researched Intercontinental Exchange Inc (ICE) on October 2nd, 2023.
Intercontinental Exchange Inc. is a prominent American multinational financial services company that operates global financial exchanges and clearing houses, and provides mortgage technology, data, and listing services. Founded in 2000 by Jeffrey Sprecher, ICE has expanded its operations to include 12 regulated exchanges and marketplaces, such as ICE futures exchanges in the U.S., Canada, and Europe, the New York Stock Exchange, and various equity options exchanges. The company also owns and operates six central clearing houses, including ICE Clear U.S., ICE Clear Europe, and ICE Clear Singapore.
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $107.59 on October 2nd, 2023.
- Our designated price target stands at $157.00
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More
ARGUS QUANTITATIVE
Argus Quantitative analyzes energy, commodities, and finance with data analytics
View More
ARGUS ANALYST
Argus Analyst Notes offers timely investment recommendations, insights.
View More
THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
View More
2025 Q1 EARNING REPORT
A Q1 report evaluates company financials for investors
Balfour Capital Group wants to clarify that our recommendation to Buy INTERCONTINENTAL EXCHANGE INC (ICE) is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
ASML
ASML HOLDING NV
(NASDAQ:ASML)
Balfour Capital Group Researched ASML Holding NVon October 3rd, 2023.
ASML Holding N.V. is a Dutch company that designs and manufactures advanced lithography machines used in the production of semiconductor chips. These machines are essential for patterning silicon wafers, enabling the creation of integrated circuits found in a wide array of electronic devices. ASML’s technology is pivotal in producing smaller, faster, and more energy-efficient chips, making it a critical player in the semiconductor industry.
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $574.95 on October 3rd, 2023.
- Our designated price target stands at $818.38
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More
ARGUS QUANTITATIVE
Argus Quantitative analyzes energy, commodities, and finance with data analytics
View More
ARGUS ANALYST
Argus Analyst Notes offers timely investment recommendations, insights.
View More
2025 Q1 EARNING REPORT
A Q5 report evaluates company financials for investors
Balfour Capital Group wants to clarify that our recommendation to Buy ASML HOLDING NV (ASML) is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
CAT
CATERPILLAR INC.
(NYSE:CAT)
Balfour Capital Group Researched Caterpillar Inc. on October 3rd, 2023.
Caterpillar Inc. is the world’s leading manufacturer of construction and mining equipment, off-highway diesel and natural gas engines, industrial gas turbines, and diesel-electric locomotives. For nearly a century, the company has been helping customers build a better, more sustainable world. Their innovative products and services, backed by a global dealer network, provide exceptional value to help customers succeed.
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $271.21 on October 3rd, 2023.
- Our designated price target stands at $400.00
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More
ARGUS QUANTITATIVE
Argus Quantitative analyzes energy, commodities, and finance with data analytics
View More
ARGUS ANALYST
Argus Analyst Notes offers timely investment recommendations, insights.
View More
THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
View More
2025 Q1 EARNING REPORT
A Q1 report evaluates company financials for investors
Balfour Capital Group wants to clarify that our recommendation to Buy Caterpillar Inc. (CAT) is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
BK
BANK OF NEW YORK MELLON COMPANY
(NYSE:BK)
Balfour Capital Group has issued a buy recommendation
for Bank of New York Mellon Company (BK) on October 16th, 2023.
The Bank of New York Mellon Corporation, headquartered in New York City, provides investment management, investment services, and wealth management. Formed from the 2007 merger of The Bank of New York and Mellon Financial Corporation, it is the world’s largest custodian bank with $1.8 trillion in assets under management and $45.7 trillion in custody.
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $41.54 on October 16th, 2023.
- Our designated price target stands at $85.75
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More
ARGUS QUANTITATIVE
Argus Quantitative analyzes energy, commodities, and finance with data analytics
View More
ARGUS ANALYST
Argus Analyst Notes offers timely investment recommendations, insights.
View More
THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
View More
2025 Q1 EARNING REPORT
A Q1 report evaluates company financials for investors
Balfour Capital Group wants to clarify that our recommendation to Buy Bank of New York Mellon Company (BK) is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
BA
THE BOEING COMPANY
(NYSE:BA)
Balfour Capital Group Researched The Boeing Company on October 24th, 2023.
The Boeing Company is a leading global aerospace and defense corporation that designs, manufactures, and sells airplanes, rotorcraft, rockets, satellites, telecommunications equipment, and missiles worldwide. The company also provides leasing and product support services. Boeing operates through four segments: Commercial Airplanes, Defense, Space & Security, Global Services, and Boeing Capital.
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $182.42 on October 24th, 2023.
- Our designated price target stands at $245.00
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More
ARGUS QUANTITATIVE
Argus Quantitative analyzes energy, commodities, and finance with data analytics
View More
ARGUS ANALYST
Argus Analyst Notes offers timely investment recommendations, insights.
View More
THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
View More
2025 Q1 EARNING REPORT
A Q1 report evaluates company financials for investors
Balfour Capital Group wants to clarify that our recommendation to Buy The Boeing Company (BA) is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
CVX
CHEVRON CORPORATION
(NYSE: CVX)
Balfour Capital Group has issued a buy recommendation
for Chevron Corporation (CVX) on December 4th, 2023
Chevron Corporation, headquartered in San Ramon, California, is an American multinational energy company specializing in oil and gas. It operates in over 180 countries and is involved in hydrocarbon exploration, production, refining, marketing, transport, chemicals manufacturing, and power generation. Chevron manufactures and sells fuels, lubricants, additives, and petrochemicals, primarily in North America, Southeast Asia, South Korea, and Australia.
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $144.81 on December 4th, 2023.
- Our designated price target stands at $190.00
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More
ARGUS QUANTITATIVE
Argus Quantitative analyzes energy, commodities, and finance with data analytics
View More
ARGUS ANALYST
Argus Analyst Notes offers timely investment recommendations, insights.
View More
THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
View More
2025 Q1 EARNING REPORT
A Q1 report evaluates company financials for investors
Balfour Capital Group wants to clarify that our recommendation to Buy Chevron Corporation (CVX) is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
ISRG
INTUITIVE SURGICAL, INC.
(NASDAQ: ISRG)
Balfour Capital Group has issued a buy recommendation
for Intuitive Surgical, Inc. (ISRG) on November 22nd, 2023
Intuitive Surgical, Inc. is an American biotechnology company specializing in robotic products for minimally invasive surgery, notably the da Vinci Surgical System. As of December 2021, it had 6,730 systems installed globally, including 4,139 in the U.S., 1,199 in Europe, and 1,050 in Asia..
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $315.00 on November 22nd, 2023.
- Our designated price target stands at $600.00
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More
ARGUS QUANTITATIVE
Argus Quantitative analyzes energy, commodities, and finance with data analytics.
View More
ARGUS ANALYST
Argus Analyst Notes offers timely investment recommendations, insights.
View More
THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
View More
2025 Q1 EARNING REPORT
A Q1 report evaluates company financials for investors
Balfour Capital Group wants to clarify that our recommendation to Buy Intuitive Surgical, Inc. (ISRG) is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
GILD
GILEAD SCIENCES, INC.
(NASDAQ: GILD)
Balfour Capital Group has issued a buy recommendation
for Gilead Sciences, Inc. (GILD) on November 23th, 2023
Gilead Sciences, Inc., headquartered in Foster City, California, is an American biopharmaceutical company focused on antiviral drugs for HIV/AIDS, hepatitis B and C, influenza, and COVID-19. Founded in 1987 as Oligogen, it developed notable drugs like Tamiflu and Vistide and evolved into a major pharmaceutical company.
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $75.89 on November 23th, 2023.
- Our designated price target stands at $104.00
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More
ARGUS QUANTITATIVE
Argus Quantitative analyzes energy, commodities, and finance with data analytics.
View More
ARGUS ANALYST
Argus Analyst Notes offers timely investment recommendations, insights.
View More
THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
View More
2025 Q1 EARNING REPORT
A Q3 report evaluates company financials for investors
Balfour Capital Group wants to clarify that our recommendation to Buy Gilead Sciences, Inc. (GILD) is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
ALNY
ALNYLAM PHARMACEUTICALS, INC.
(NASDAQ: ALNY)
Balfour Capital Group has issued a buy recommendation for Alnylam Pharmaceuticals, Inc. (ALNY) on Nov. 26th, 2023.
Alnylam Pharmaceuticals, Inc., founded in 2002 and headquartered in Cambridge, Massachusetts, is an American biopharmaceutical company specializing in RNA interference (RNAi) therapeutics for genetically defined diseases. In 2016, Forbes recognized it as one of the “100 Most Innovative Growth Companies.”
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $162.98 on November 26th, 2023.
- Our designated price target stands at $300.00
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More
THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
View More
2025 Q1 EARNING REPORT
A Q1 report evaluates company financials for investors
Balfour Capital Group wants to clarify that our recommendation to Buy Alnylam Pharmaceuticals, Inc. (ALNY) is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
